Sugimoto, Shinya

写真a

Affiliation

School of Medicine, The Sakaguchi Laboratory - Department of Organoid Medicine (Shinanomachi)

Position

Assistant Professor (Non-tenured)/Research Associate (Non-tenured)/Instructor (Non-tenured)

Academic Background 【 Display / hide

  • 2003.04
    -
    2009.03

    Keio University, School of Medicine

    University, Graduated

  • 2014.04
    -
    2018.03

    Keio University, 医学研究科医学研究系専攻

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(医学), Keio University, Coursework, 2018.03

    Reconstruction of the Human Colon Epithelium In Vivo

 

Research Areas 【 Display / hide

  • Gastroenterology

Research Keywords 【 Display / hide

  • オルガノイド

  • 炎症性腸疾患

  • 腸管上皮幹細胞

 

Papers 【 Display / hide

  • Wnt Signaling Shapes the Histological Variation in Diffuse Gastric Cancer.

    Togasaki K, Sugimoto S, Ohta Y, Nanki K, Matano M, Takahashi S, Fujii M, Kanai T, Sato T

    Gastroenterology 160 ( 3 ) 823 - 830 2020.11

    ISSN  0016-5085

  • An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.

    Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T

    Cell (Cell)  183 ( 5 ) 1420 - 1435.e21 2020.10

    ISSN  0092-8674

     View Summary

    © 2020 Elsevier Inc. Gastroenteropancreatic (GEP) neuroendocrine neoplasm (NEN) that consists of neuroendocrine tumor and neuroendocrine carcinoma (NEC) is a lethal but under-investigated disease owing to its rarity. To fill the scarcity of clinically relevant models of GEP-NEN, we here established 25 lines of NEN organoids and performed their comprehensive molecular characterization. GEP-NEN organoids recapitulated pathohistological and functional phenotypes of the original tumors. Whole-genome sequencing revealed frequent genetic alterations in TP53 and RB1 in GEP-NECs, and characteristic chromosome-wide loss of heterozygosity in GEP-NENs. Transcriptome analysis identified molecular subtypes that are distinguished by the expression of distinct transcription factors. GEP-NEN organoids gained independence from the stem cell niche irrespective of genetic mutations. Compound knockout of TP53 and RB1, together with overexpression of key transcription factors, conferred on the normal colonic epithelium phenotypes that are compatible with GEP-NEN biology. Altogether, our study not only provides genetic understanding of GEP-NEN, but also connects its genetics and biological phenotypes. Gastroenteropancreatic neuroendocrine neoplasms are a rare but lethal cancer with a scarcity of clinically relevant models. Kawasaki et al. establish and characterize 25 organoid lines to identify molecular subtypes with genotype-phenotype mapping.

  • Water-assisted colonoscopy: an international modified Delphi review on definitions and practice recommendations.

    Cadoni S, Ishaq S, Hassan C, Falt P, Fuccio L, Siau K, Leung JW, Anderson J, Binmoeller KF, Radaelli F, Rutter MD, Sugimoto S, Muhammad H, Leung FW, International WATERS and modified Delphi respondents groups.

    Gastrointestinal endoscopy (Gastrointestinal Endoscopy)   2020.10

    ISSN  0016-5107

     View Summary

    © 2020 American Society for Gastrointestinal Endoscopy Background and Aims: Since 2008, a plethora of research studies has compared the efficacy of water-assisted (aided) colonoscopy (WAC) and underwater resection (UWR) of colorectal lesions with standard colonoscopy. We reviewed and graded the research evidence with potential clinical application. We conducted a modified Delphi consensus among experienced colonoscopists on definitions and practice of water immersion (WI), water exchange (WE), and UWR. Methods: Major databases were searched to obtain research reports that could potentially shape clinical practice related to WAC and UWR. Pertinent references were graded (Grading of Recommendations, Assessment, Development and Evaluation). Extracted data supporting evidence-based statements were tabulated and provided to respondents. We received responses from 55 (85% surveyed) experienced colonoscopists (37 experts and 18 nonexperts in WAC) from 16 countries in 3 rounds. Voting was conducted anonymously in the second and third round, with ≥80% agreement defined as consensus. We aimed to obtain consensus in all statements. Results: In the first and the second modified Delphi rounds, 20 proposed statements were decreased to 14 and then 11 statements. After the third round, the combined responses from all respondents depicted the consensus in 11 statements (S): definitions of WI (S1) and WE (S2), procedural features (S3-S5), impact on bowel cleanliness (S6), adenoma detection (S7), pain score (S8), and UWR (S9-S11). Conclusions: The most important consensus statements are that WI and WE are not the same in implementation and outcomes. Because studies that could potentially shape clinical practice of WAC and UWR were chosen for review, this modified Delphi consensus supports recommendations for the use of WAC in clinical practice.

  • Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis

    Naganuma M., Kobayashi T., Nasuno M., Motoya S., Kato S., Matsuoka K., Hokari R., Watanabe C., Sakamoto H., Yamamoto H., Sasaki M., Watanabe K., Iijima H., Endo Y., Ichikawa H., Ozeki K., Tanida S., Ueno N., Fujiya M., Sako M., Takeuchi K., Sugimoto S., Abe T., Hibi T., Suzuki Y., Kanai T.

    Clinical Gastroenterology and Hepatology (Clinical Gastroenterology and Hepatology)  18 ( 5 ) 1102 - 1111.e5 2020.05

    ISSN  15423565

     View Summary

    © 2020 AGA Institute Background & Aims: We compared the diagnostic accuracy of the fecal calprotectin (FCP) test vs the fecal immunochemical blood test (FIT) in determining the endoscopic severity and predicting outcomes of patients with ulcerative colitis (UC). Methods: We performed a nationwide study of 879 patients with UC, enrolled at medical centers across Japan, from March 2015 to March 2017. We collected data on fecal biomarkers, endoscopic severities, and other clinical indices from Cohort 1 (n = 427) and assessed the diagnostic accuracy of FCP measurement and FIT results in determining clinical severity, based on Mayo score, and endoscopic remission, based on Mayo endoscopic sub-score (MES) or UC endoscopic index of severity. We also followed 452 patients in clinical remission from UC (Cohort 2) for 12 months and evaluated the associations of FCP levels and FIT results with clinical recurrence. Results: The levels of FCP and FIT each correlated with the MES and UC endoscopic index of severity. There were no significant differences in the areas under the curve of FCP vs FIT in distinguishing patients with MES≤1 from those with MES≥2 (P = .394) or in distinguishing patients with MES=0 from those with MES≥1 (P = .178). Among 405 patients in clinical remission at baseline, 38 (9.4%) had UC recurrences within 3 months and 90 (22.2%) had recurrences within 12 months. FCP≥146 mg/kg (hazard ratio [HR], 4.83; 95% confidence interval [CI], 2.80-8.33) and FIT≥77 ng/mL (HR, 2.92; 95% CI, 1.76-4.83) were independently associated with clinical recurrence within 12 months. UC recurred within 12 months in 69% of patients with levels of FCP≥146 mg/kg and FIT ≥77 ng/mL; this value was significantly higher than the rate of recurrence in patients with levels of FCP≥146 mg/kg and FIT <77 ng/mL (31.5%, P < .001) or patients with levels of FCP<146 mg/kg and FIT ≥77 ng/mL (30.0%, P < .001). Conclusion: In a nationwide study of patients with UC in Japan, we found that the level of FCP and FIT could each identify patients with endoscopic markers of disease severity (MES≥2). The combination of FCP and FIT results can identify patients in remission who are at risk for disease recurrence. Clinical Trials Registry no: UMIN000017650 (http://www.umin.ac.jp/ctr/)

  • Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study

    Naganuma M., Sugimoto S., Fukuda T., Mitsuyama K., Kobayashi T., Yoshimura N., Ohi H., Tanaka S., Andoh A., Ohmiya N., Saigusa K., Yamamoto T., Morohoshi Y., Ichikawa H., Matsuoka K., Hisamatsu T., Watanabe K., Mizuno S., Abe T., Suzuki Y., Kanai T., Naganuma M., Nakazato Y., Teratani T., Ogata H., Iwao Y., Yamasaki H., Toyonaga T., Nakano M., Hibi T., Sameshima Y., Hayashi R., Ueno Y., Bamba S., Watanabe M., Nakazawa A., Koike Y., Imai J., Shimoyama T., Takeuchi K., Nagasaka M., Kitano A., Ashizuka S., Inatsu H., Onodera K., Nakase H., Kitamura K., Ikeya K., Hanai H., Watanabe C., Hokari R., Hirai F., Naito Y., Hoshi N., Kinjo F., Ishiguro Y., Sasaki M., Matsumoto T., Sano F., Roberts R., Suda W., Hattori M., Fukuda S., Hirayama A.

    Journal of Gastroenterology (Journal of Gastroenterology)  55 ( 2 ) 169 - 180 2020.02

    ISSN  09441174

     View Summary

    © 2019, Japanese Society of Gastroenterology. Background: We recently reported the efficacy of indigo naturalis (IN) in patients with active ulcerative colitis (UC) in a randomized controlled trial (INDIGO study). However, few studies have been conducted to investigate whether IN is effective even in treatment-refractory cases, such as in those with steroid dependency and anti-TNF refractoriness. Methods: In the INDIGO study, 86 patients with active UC were randomly assigned to an IN group (0.5–2.0 g daily) or placebo group. The rate of clinical response (CR), mucosal healing (MH), and change in fecal calprotectin (FCP) levels was compared between refractory [patients with steroid-dependent disease, previous use of anti-TNF-α, and concomitant use of immunomodulators (IM)] and non-refractory patients. We also analyzed factors predicting CR and MH at week 8. Results: The rates of CR of IN group were significantly higher than placebo group, even in patients with steroid-dependent disease (p < 0.001), previous use of anti-TNF-α (p = 0.002), and concomitant use of IM (p = 0.013). The rates of MH in IN group were significantly higher than in placebo group in patients with steroid-dependent disease (p = 0.009). In the IN group, median FCP levels, at week 8, were significantly lower than baseline in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α (p < 0.001, respectively). Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. Conclusions: In a sub-analysis of data from a randomized placebo-controlled trial, we found that IN may be useful even in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

Research Projects of Competitive Funds, etc. 【 Display / hide

  • Functional analysis of small intestinal epithelial organoid-based transplant graft

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 杉本 真也, Grant-in-Aid for Scientific Research (B), Principal Investigator

  • 腸管AhRワールドの解明

    2019.02
    -
    2021.03

    文部科学省・日本学術振興会, 科学研究費助成事業, 金井 隆典, Promotion of Joint International Research (Fostering Joint International Research (B)), Co-investigator

  • 腸管上皮-間質ニッチの包括的理解と自己補完的組織培養技術の確立

    2015.04
    -
    2018.03

    文部科学省・日本学術振興会, 科学研究費助成事業, 杉本 真也, 特別研究員奨励費, Principal Investigator

Awards 【 Display / hide

  • 若手奨励賞

    2019.11, JDDW

    Type of Award: Awards of National Conference, Council and Symposium

  • Medical Research Encouragement Prize of the Tokyo Medical Association

    2019.03, The Tokyo Medical Association

    Type of Award: Awards of Publisher, Newspaper Company and Foundation

  • Inoue Research Award for Young Scientists

    2019.02, Inoue Foundation for Science

    Type of Award: Awards of Publisher, Newspaper Company and Foundation

  • Young Investigator Award

    2018.06, Keio University School of Medicine Alumni Association

    Type of Award: Keio commendation etc.

  • Young Investigator Award

    2017.02, The Japanese Gastroenterological Association

    Type of Award: Celebration by Official journal of a scientific society or Academic Journal

display all >>